These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 27626702)

  • 1. Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy.
    Williams GS; Mistry B; Guillard S; Ulrichsen JC; Sandercock AM; Wang J; González-Muñoz A; Parmentier J; Black C; Soden J; Freeth J; Jovanović J; Leyland R; Al-Lamki RS; Leishman AJ; Rust SJ; Stewart R; Jermutus L; Bradley JR; Bedian V; Valge-Archer V; Minter R; Wilkinson RW
    Oncotarget; 2016 Oct; 7(42):68278-68291. PubMed ID: 27626702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer.
    Nie Y; He J; Shirota H; Trivett AL; Yang D; Klinman DM; Oppenheim JJ; Chen X
    Sci Signal; 2018 Jan; 11(511):. PubMed ID: 29295954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNFR2: A Novel Target for Cancer Immunotherapy.
    Vanamee ÉS; Faustman DL
    Trends Mol Med; 2017 Nov; 23(11):1037-1046. PubMed ID: 29032004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
    Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
    Front Immunol; 2018; 9():583. PubMed ID: 29623079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing TNFR2 antagonism for immunotherapy with tumor microenvironment specificity.
    Yang M; Tran L; Torrey H; Song Y; Perkins H; Case K; Zheng H; Takahashi H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):971-980. PubMed ID: 32202358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models.
    Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL
    J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor receptor 2-dependent homeostasis of regulatory T cells as a player in TNF-induced experimental metastasis.
    Chopra M; Riedel SS; Biehl M; Krieger S; von Krosigk V; Bäuerlein CA; Brede C; Jordan Garrote AL; Kraus S; Schäfer V; Ritz M; Mattenheimer K; Degla A; Mottok A; Einsele H; Wajant H; Beilhack A
    Carcinogenesis; 2013 Jun; 34(6):1296-303. PubMed ID: 23385062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNFR2-expressing CD4
    He J; Li R; Chen Y; Hu Y; Chen X
    Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNFR1 delivers pro-survival signals that are required for limiting TNFR2-dependent activation-induced cell death (AICD) in CD8+ T cells.
    Twu YC; Gold MR; Teh HS
    Eur J Immunol; 2011 Feb; 41(2):335-44. PubMed ID: 21268004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs.
    Torrey H; Butterworth J; Mera T; Okubo Y; Wang L; Baum D; Defusco A; Plager S; Warden S; Huang D; Vanamee E; Foster R; Faustman DL
    Sci Signal; 2017 Jan; 10(462):. PubMed ID: 28096513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Autocrine TNFα-Tumor Necrosis Factor Receptor 2 Loop Promotes Epigenetic Effects Inducing Human Treg Stability
    Urbano PCM; Koenen HJPM; Joosten I; He X
    Front Immunol; 2018; 9():573. PubMed ID: 29619032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
    Zou H; Li R; Hu H; Hu Y; Chen X
    Front Immunol; 2018; 9():594. PubMed ID: 29632537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonistic Antibody Targeting TNFR2 Inhibits Regulatory T Cell Function to Promote Anti-Tumor Activity.
    Chen Y; Jia M; Wang S; Xu S; He N
    Front Immunol; 2022; 13():835690. PubMed ID: 35251028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNFR2 increases the sensitivity of ligand-induced activation of the p38 MAPK and NF-κB pathways and signals TRAF2 protein degradation in macrophages.
    Ruspi G; Schmidt EM; McCann F; Feldmann M; Williams RO; Stoop AA; Dean JL
    Cell Signal; 2014 Apr; 26(4):683-90. PubMed ID: 24378531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scutellarin enhances anti-tumor immune responses by reducing TNFR2-expressing CD4
    Chen S; Li R; Chen Y; Chou CK; Zhang Z; Yang Y; Liao P; Wang Q; Chen X
    Biomed Pharmacother; 2022 Jul; 151():113187. PubMed ID: 35676787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology.
    Salomon BL; Leclerc M; Tosello J; Ronin E; Piaggio E; Cohen JL
    Front Immunol; 2018; 9():444. PubMed ID: 29593717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNFR2 antagonistic antibody induces the death of tumor infiltrating CD4
    He T; Chen Y; Yang D; Islam MS; Chou CK; Liu J; Faustman DL; Oppenheim JJ; Chen X
    Cell Oncol (Dordr); 2023 Feb; 46(1):167-177. PubMed ID: 36369606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNFR2 pathways are fully active in cancer regulatory T cells.
    Okuzono Y; Muraki Y; Sato S
    Biosci Biotechnol Biochem; 2022 Feb; 86(3):351-361. PubMed ID: 35015831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNFR2 deficiency impairs the growth of mouse colon cancer.
    Li P; Yang Y; Yang X; Wang Y; Chou CK; Jiang M; Zheng J; Chen F; Chen X
    Int J Biol Sci; 2023; 19(4):1024-1035. PubMed ID: 36923938
    [No Abstract]   [Full Text] [Related]  

  • 20. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2.
    Hu X; Li B; Li X; Zhao X; Wan L; Lin G; Yu M; Wang J; Jiang X; Feng W; Qin Z; Yin B; Li Z
    J Immunol; 2014 Feb; 192(3):1320-31. PubMed ID: 24379122
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.